 |
|
|
| |
High SVR Rates (SVR4) for 12-Week Total Telaprevir Combination Therapy in IL28B CC Treatment-Naïves and Prior Relapsers With G1 Chronic Hepatitis C: CONCISE Interim Analysis
|
| |
| |
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
DR Nelson,1 F Poordad,2 JJ Feld,3 MW Fried,4 IM Jacobson,5 PJ Pockros,6 MS Sulkowski,7 S Zeuzem,8 L Bengtsson,9 S George,9 MI Friedman,9 on behalf of the CONCISE Study Team
1University of Florida College of Medicine, Gainesville, FL, USA; 2University of Texas Health Science Center, San Antonio, TX, USA; 3Toronto Western Hospital Liver Center, Toronto, ON, CAN; 4University of North Carolina School of Medicine, Chapel Hill, NC, USA; 5Weill Cornell Medical College, New York, NY, USA; 6Scripps Clinic, La Jolla, CA, USA; 7Johns Hopkins University School of Medicine, Baltimore, MD, USA; 8Johann Wolfgang Goethe University Hospital, Frankfurt/Main, DE; 9Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA
|
| |
|
|
|
|
|
